G
o
o
g
l
e
×
Please click
here
if you are not redirected within a few seconds.
All
News
Videos
Images
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
What Makes Veru (VERU) a New Buy Stock
Yahoo Finance
Veru (VERU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
1 day ago
Veru needs cash for fresh trial of respiratory distress drug
Fierce Biotech
Veru needs additional cash for fresh trial of respiratory distress drug ... Veru knows the route that its once-dismissed respiratory distress drug...
2 months ago
Veru (NASDAQ:VERU) Earns “Outperform” Rating from Oppenheimer
Defense World
Read Veru (NASDAQ:VERU) Earns “Outperform” Rating from Oppenheimer at Defense World.
2 days ago
FDA clears Veru’s IND for GLP-1 RA-associated muscle loss drug
Pharmaceutical Technology
Veru's Ostarine has previously been investigated in five clinical studies in patients with muscle wastage caused by advanced cancer.
2 months ago
Veru's Leaders Allegedly Overstated Covid-19 Drug's FDA Progress
Bloomberg Law News
Biopharmaceutical company Veru Inc. officers and directors allegedly implied the company's drug candidate for treating adults hospitalized...
7 months ago
FDA clears Veru's IND for GLP-1 RA-associated muscle loss drug
Home - GlobalData
FDA clears Veru's IND for GLP-1 RA-associated muscle loss drug. The company intends to start enrolling patients for both multicentre clinical studies in the...
4 days ago
Veru Faces Nasdaq Delisting Over Price Compliance Issue - TipRanks.com
Tipranks
Veru (VERU) has released an update to notify the public and investors about listing compliance status. Veru Inc. received a notification from Nasdaq on...
2 months ago
Veru Reschedules Annual Meeting of Shareholders
GlobeNewswire
Veru Reschedules Annual Meeting of Shareholders · --Restated historical financial statements expected to be filed no later than April 15, 2024--.
4 weeks ago
Oppenheimer cuts Veru stock target, remains Outperform rated on enobosarm potential
Investing.com Canada
On Monday, Oppenheimer adjusted its price target for Veru Inc. (NASDAQ:VERU), a biopharmaceutical company, reducing it to $5.00 from the...
3 days ago
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
Yahoo Finance
MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing...
1 month ago